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Behcet’s disease (BD) is a chronic disease which is characterized by recurrent oral apthous ulcerations, recurrent genital ulcera-
tions, skin eruptions, ocular involvements and other various systemic manifestations as well as systemic vasculitis. Endocrine
involvement in BD regarding various systems can be seen. Hypophysis is one of the best and dense vascularized organs of the
body, thus it is likely that it can be aﬀected by BD. Not only anterior hypophysis functions, but posterior hypophysis functions as
well can be aﬀected. As BD is a disease of autoimmune process, it may be possible that adrenal insuﬃciency or alterations in the
cortisol levels could be expected. Another concern is whether or not there is insulin resistance in patients with BD. The avaliable
data suggests that there is an increased susceptibility to insulin resistance in patients with BD.
1.Introduction
Behcet’s disease (BD) is a chronic disease which is character-
ized byrecurrentoral aphthous ulcerations,recurrentgenital
ulcerations, skin eruptions, ocular involvements, and other
v a r i o u ss y s t e m i cm a n i f e s t a t i o n sa sw e l la ss y s t e m i cv a s c u l i t i s
[1]. Endocrine involvement in BD regarding various systems
can be seen. Here with this paper we have tried to review the
literature in terms of BD “eﬀects” on endocrine system.
2.Behcet’s Disease andHypophysis
Hypophysisisoneofthebestanddensestvascularizedorgans
of the body, thus it is likely that it can be aﬀected by BD [2].
There are several studies regarding this fact in the literature.
Inoneofthesestudies,Akdenizetal.hadstudiedthebaseline
and stimulated thyroid functions in BD. They recruited 30
patients consisting of 17 males and 13 females and 30 control
subjects to their study. Thyroid function tests baseline and
TSH levels at the 20th and 60th minutes after the adminis-
trationofTRHwereevaluated.Inconclusiontheystatedthat
thyroid functions were normal in patients with BD; however,
TRH stimulation was found to be decreased [3]. In another
study where thyroid functions were evaluated, Aksu et al.,
found that thyroid function tests were within normal range
in patients with BD; however, they did not assess the TRH-
stimulated TSH levels [4]. Posterior hypophysis functions
can also be aﬀected in patients with BD which can represent
itselfwithdiabetesinsipudus.Eventhoughthisentityisarare
feature of BD, there are several case reports being reported in
the literature. In one of these, Khiari et al. reported that a
47-year-old man presented with oral and genital ulcers, skin
lesions, and polyarthralgia. Two years after his ﬁrst applica-
tion he started to suﬀer from right uveitis and central di-
abetesinsipiduswithoutdysfunctionoftheanteriorpituitary
[5].InanothercasereportSzymajdaetal.,fromUSA,report-
ed a 32-year-old man with diplopia and severe headaches
who had transverse sinus thrombosis at the same time. They
also stated that the patient was suﬀering from recurrent
mouth and genital ulcers for more than 3 months before his
application. During his hospitalization, the patient was re-
ported having polyuria, polydipsia, hypernatremia, and
hypotonic urine which were the stigmatas of diabetes insip-
idus. After the diagnosis, desmopressin was started and im-
provement in clinical status was achieved. As the mechanism
of this pathology, vasculitis was accused [6]. Jin-No et al. [7],
Otsuka et al. [8], and Hamza et al. [9], have studies also re-
garding the relationship between BD and diabetes insipidus.2 Pathology Research International
Another interesting question which has been a concern
for recent years is: does prolactin levels have eﬀect on the ac-
tivation of BD? There are some studies available in the liter-
ature regarding this subject. In one of these studies C ¸iletal.
found no signiﬁcant diﬀerence in terms of hormone levels
between the Behcet and control groups [10]. However in an-
other study, Proenc ¸ha et al. reported that serum prolactin
levels were signiﬁcantly higher in BD patients versus controls
[11]. Another study by Atasoy et al. also had declared that
patients with active BD had higher serum prolactin levels
than the inactive and control groups. In their study prolactin
levels in patients with active BD diﬀered signiﬁcantly from
the healthy control subjects [12]. Nevertheless, a study which
was conducted by Houman et al., found that the mean pro-
lactin level in the BD group (mean = 13.76, SD = 6.82), was
higherthanthecontrolgroup(mean=10.13,SD=5.46)with
no statistically signiﬁcant diﬀerence. Also the mean prolactin
levels in all subgroups of patients with BD were higher than
normal, but no statistically signiﬁcant diﬀerence was shown
between these subgroups [13]. The exact mechanisms of why
prolactin is increased in BD remains unclear; however, there
are some facts which has been suggested responsible. Pro-
lactin has been shown to be an important modulator of cel-
lular and humoral immunity which may play a role in the
pathogenesis of several autoimmune diseases such as rheu-
matoid arthritis [14–16]. Increased prolactin levels and dis-
ease activity of systemic lupus erythematosus have been
found to be associated with each other as well [17]. In this
context, since BD is also a rheumatic disease of autoimmune
basis, it might be suggested that prolactin levels could be
elevated.
3.Behcet’s DiseaseandAdrenalGlands
As BD is a disease of autoimmune process, it may be possible
that adrenal insuﬃciency or alterations in the cortisol levels
could be expected. Taking this fact into consideration Colak
et al. had conducted a study investigating the eﬀects of low-
(1microg; LDT) and standard- (250microg; SDT) dose
ACTH stimulation tests on adrenal cortex functions in pa-
tients with Behcet’s disease; 18 patients with BD and 15 con-
trolswererecruitedtothisstudy.Boththepatientandcontrol
groups were administered 1 microgram and 250 micrograms
of ACTH, respectively, with 3-day intervals in between and
responses of cortisol at the 0th, 30th, and 60th minutes after
theadministrationofACTHwereevaluated.Theyfoundthat
there was no statistically signiﬁcant diﬀerence between basal
cortisol levels of BD and the control group; however, cortisol
levels in the 60th minute of LDT were signiﬁcantly low in
patients with Behcet as compared to the control group. The
peak cortisol responses to LTD were found to be decreased
in Behcet’s group as well. In this context they suggested that
hypothalamopituitaryaxisispartiallysuppressedinBD[18].
Ac a s er e p o r tb yS´ anchez Sobrino et al., from Spain reports a
longstandingBehcet’spatientdevelopingadrenalinsufﬁcien-
cy, caused by isolated corticotropin deﬁciency. In this sense
they reviewed the literature for the possible mechanisms of
hypothalamic-pituitary injury in BD [19].
4.Behcet’s Disease andInsulinResistance
Another concern and studied subject is whether or not there
is insulin resistance in patients with BD. In one of these stud-
ies Kim et al., evaluated this subject. They recruited 82 BD
patients and 89 healthy controls to the study and measured
the resistin and adiponectin levels at the time of enrolment
along with the HOMA-IR evaluation with fasting plasma
glucose and insulin levels. As their result they declared that
there is an increased susceptibility to insulin resistance in pa-
tients with BD as compared to the controls and resistin could
be an independent factor for this resistance [20]. In another
study where peripheral insulin resistance was assessed with
hyperinsulinemic-euglycaemic glucose clamp technique, Er-
dem et al., from Turkey, found that patients with BD exhibit
peripheral insulin resistance which was thought to be be-
cause of inﬂammation and endothelial dysfunction [21].
5. Conclusion
With this review we have tried to have a look at what has
been studied and evaluated in the literature regarding the
relationship between BD and certain endocrine subjects via
PubMed. As it may be seen, the available data is not too
much. Since BD is a disease of autoimmunity and many dis-
eases related with endocrinology have autoimmunity basis,
we believe that further studies should be performed to un-
derstand if BD and at least some endocrine diseases interact
with each other.
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